PubMed Health⌕ Search

Biomedical subjects

G Mitrou

Publications and source records attributed to G Mitrou.

13 recordsLinked to original sources
PubMed1988

[Therapy of alopecia areata with diphenylcyclopropenone].

With special regard to practical aspects, we discuss the treatment of alopecia areata by topical immunotherapy with diphenylcyclopropenone. Out of 27 patients treated this way, 10 patients showed good and cosmetically acceptable regrowth of terminal hair; 11 patients showed some regrowth, which was not satisfactory, however, for cosmetic reasons; 6 patients developed no hair growth at all. The complete failure of treatment in the latter cases may possibly be due to the long duration of the alopecia.

Administration, Topical↗
PubMed1987

[Symptomatic livedo racemosa in cholesterol embolism with occlusion of the arterioles in the area of the corium-subcutis].

We report on a 70-year-old woman suffering from diabetes mellitus dependent on insulin and associated with malignant hypertension. Following heart catheter examination for the dilatation of the renal arteries, she developed acute, painful, persistent livedo racemosa of the buttocks and the lower extremities. Histological investigation revealed embolism of cholesterol crystals in arterioles of the corium-subcutis region. On the basis of the cases described in the literature so far, we discuss the clinical spectrum of cutaneous cholesterol embolism.

Aged↗
PubMed1979

[Methods for the detection of antibodies to native (double stranded) DNA (author's transl)].

Three different methods adequate for routine work, i.e. hemagglutination, counterimmunoelectrophoresis and radioimmunoassay, were used in the past in our laboratory to detect antibodies to native (double stranded) DNA. There was a high incidence of false positive or false negative results by counterimmunoelectrophoresis. Hemagglutination reaction was less sensitive in detecting anti-nDNA than was radioimmunoassay. Natural DNA preparations and a synthetic polynucleotide (3H-dAT) were used as antigenic substrates in radioimmunoassay providing well correlating binding values.

Antibodies↗
PubMed1979

The oncogenic effect of immunosuppressive (cytotoxic) agents in (NZB X NZW) mice. I. Long-term treatment with azathioprine and ifosfamide.

The increased incidence of neoplasia in the chronic use of immunosuppressive agents has been linked to a variety of factors including age, dose, agent, and frequency of administration. In this study azathioprine (az) and ifosfamide (ifo) were given both daily and weekly to female (NZB X NZW) mice over a period of 14 or 16 months in various dose regimens. Daily treatment with both agents prolonged survival time significantly but induced an apparently dose-related increase in tumor frequency. Intermittent ifo therapy produced neoplasia and survival results comparable to daily treatment, whereas intermittent az failed to extend longevity or produce malignancies. Varying the age of the mice (180 vs. 120 days) at the outset of treatment did not materially affect results in any respect. Ifo is less toxic than az in doses prolonging survival.

Animals↗
PubMed1979

The oncogenic effect of immunosuppressive (cytotoxic) agents in (NZB x NZW) mice. II. Emergence of tumors in young animals treated with azathioprine and ifosfamide, including a histologic assessment of the neoplasms.

The age of (NZB x NZW) mice treated with immunosuppressive agents has been associated with an increased incidence of neoplastic disease in certain experimental situations. In this study, azathioprine administered daily over a period of 7 to 8 months significantly increased the occurrence of malignancies in animals aged 6 to 12 weeks at the start of treatment. No such increase was observed for ifosfamide. The resulting lesions observed in azathioprine and ifosfamide treated hybrids were predominantly lymphomas (60 to 80%) and could be classified according to two histologic types: Type I and II. The lymphomas in the ifosfamide groups could not be distinguished histologically from those in the azathioprine groups.

Animals↗
PubMed1975

[Classification and immunosuppressive therapy of systemic lupus erythematosus: long-term follow-up of 31 patients (author's transl)].

The course of systemic lupus erythematosus (SLE) in 34 patients receiving prednisone and immunosuppressive (cytotoxic) drugs is described. 31 patients are in continuous ambulatory care, 27 of them 3 to 17 years. Only two were hospitalized for therapeutic purposes: one patient because of exacerbation of lung tuberculosis; the second patient, who discontinued prednisone therapy despite active SLE, because of severe autoimmune haemolytic anaemia. The retrospective analysis of symptoms demonstrated that only 22 of the 31 patients manifested 4 or more of the prelimievious reports. Two patients with severe lupus glomerulonephritis and azotaemia at the time of initial evaluation did not benefit from combined therapy. Nine patients with mesangial and focal glomerulonephritis have normal kidney function up to 12 years after diagnosis (in two cases kidney function improved after therapy).

Adult↗